Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 8/20 | 1.00 |
| ▸ | RAB9A | P51151 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | HTT | P42858 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.89 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.69 |
| ▸ | RELA | Q04206 | 1/20 | 0.69 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.69 |
| ▸ | CNR1 | P21554 | 3/20 | 0.68 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29533340 | 1.00 | MEN1 (1.00) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL2682054 | 0.94 | KMT2A (1.00) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL30599810 | 0.93 | MEN1 (0.86) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL23069078 | 0.93 | MEN1 (0.86) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL11049956 | 0.91 | MEN1 (0.85) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL4301183 | 0.89 | KMT2A (0.82) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL29077780 | 0.89 | MEN1 (0.89) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL29556162 | 0.89 | MEN1 (0.89) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL1514631 | 0.88 | RAB9A (0.79) | MEN1KMT2ARAB9ANPC1MAPT | |
| SCHEMBL24272428 | 0.87 | MEN1 (0.79) | MEN1KMT2ARAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240409504-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-09-26 | — | — | US | disclosed |
| US-12098117-B2 | Compositions and methods for the treatment of cancer | DUKE UNIVERSITY (US) | 2024-09-24 | — | — | US | disclosed |
| US-20220106265-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY (US) | 2022-04-07 | — | — | US | disclosed |
| EP-3894392-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Duke University (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20200383331-A1 | COMPOSITIONS AND METHODS FOR LARGE-SCALE IN VITRO PLANT BIOCULTURE | BOOSHOOT LLC (US) | 2020-12-10 | — | — | US | disclosed |
| WO-2020123675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2020123675-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY (US) | 2020-06-18 | — | — | WO | disclosed |
| WO-2013016198-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR MICROPROPAGATION OF PLANTS | BOOSHOOT LLC (US) | 2013-01-31 | — | — | WO | disclosed |
| WO-2012097380-A1 | COMPOSITIONS AND METHODS FOR BAMBOO PULPING | The Red Triangle, LLC (US) | 2012-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409504-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | MEN1 4220/4885KMT2A 3139/4885RAB9A 3091/4885 |
| US-20200383331-A1 | COMPOSITIONS AND METHODS FOR LARGE-SCALE IN VITRO PLANT BIOCULTURE | MYB, MYCBP, PIM1 | MEN1 3748/4885KMT2A 2151/4885RAB9A 4167/4885 |
| US-12098117-B2 | Compositions and methods for the treatment of cancer | HSF1, HSP90AB1, HSP90AA1 | MEN1 4220/4885KMT2A 3139/4885RAB9A 3091/4885 |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | MEN1 4220/4885KMT2A 3139/4885RAB9A 3091/4885 |
| US-20220106265-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | MEN1 4220/4885KMT2A 3139/4885RAB9A 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.